Literature DB >> 11113730

Metabolic investigation of recurrent nephrolithiasis: compliance with recommendations.

J Krepinsky1, A J Ingram, D N Churchill.   

Abstract

OBJECTIVES: Nephrolithiasis is a recurrent condition with significant associated morbidity and economic impact. Although urologic intervention addresses symptomatic stone episodes, prevention of recurrences with proven medical therapy is indicated.
METHODS: This retrospective study examined 97 patients who presented in 1997 and 1998 with recurrent nephrolithiasis in a large tertiary care center for the presence of an appropriate metabolic investigation as recommended by the National Institutes of Health Consensus Conference. Complete data were abstracted from the hospital and private clinic charts.
RESULTS: The average patient age was 50.5 years; 61.9% of patients were men. The mean number of stones per patient was 5.6 (range 2 to 62), with stone analysis performed for 78 patients. Fifty-eight stones (74.4%) were calcium oxalate and/or phosphate, 14 (17.9%) urate, 8 (10.3%) struvite, and 3 (3.8%) cystine. Five patients had two stone types on different occasions. Either lithotripsy or a urologic procedure was required for at least one stone presentation in 89 patients (91.8%). An investigation for stone disease was pending in 54 patients (55.7%). A complete evaluation, satisfying the preset criteria, was performed in 34 patients (35.1%). Six patients who did not undergo evaluation were lost to follow-up. Univariate analysis revealed that referral to a nephrologist (P = 0.001), treatment with medications used for stone disease (P = 0.008), and urate stones (P = 0.005) were associated with a complete investigation. Similarly, these were independently associated with a complete evaluation in regression analysis of 77 complete data sets, with odds ratios of 24.4 (nephrology referral), 4.9 (medication use), and 5.6 (urate stones).
CONCLUSIONS: The results of this study demonstrate that a significant proportion of patients with recurrent nephrolithiasis do not undergo appropriate metabolic investigations. Efforts should be made to improve the evaluation of these patients.

Entities:  

Mesh:

Year:  2000        PMID: 11113730     DOI: 10.1016/s0090-4295(00)00822-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Laser-induced breakdown spectroscopy is a reliable method for urinary stone analysis.

Authors:  Nazım Mutlu; Seyfettin Çiftçi; Turgay Gülecen; Belgin Genç Öztoprak; Arif Demir
Journal:  Turk J Urol       Date:  2016-03

2.  Hypercalciuria, hyperoxaluria, and hypocitraturia screening from random urine samples in patients with calcium lithiasis.

Authors:  Miguel Angel Arrabal-Polo; Salvador Arias-Santiago; María Sierra Girón-Prieto; Felix Abad-Menor; Fernando López-Carmona Pintado; Armando Zuluaga-Gomez; Miguel Arrabal-Martin
Journal:  Urol Res       Date:  2012-04-07

3.  Vascular endothelial growth factor gene polymorphism is associated with calcium oxalate stone disease.

Authors:  Wen-Chi Chen; Huey-Yi Chen; Hsi-Chin Wu; Mei-Chen Wu; Cheng-Der Hsu; Fuu-Jen Tsai
Journal:  Urol Res       Date:  2003-04-29

Review 4.  Pharmacology of stone disease.

Authors:  Khashayar Sakhaee
Journal:  Adv Chronic Kidney Dis       Date:  2009-01       Impact factor: 3.620

5.  Renal geology (quantitative renal stone analysis) by 'Fourier transform infrared spectroscopy'.

Authors:  Iqbal Singh
Journal:  Int Urol Nephrol       Date:  2008-01-26       Impact factor: 2.370

6.  Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.

Authors:  A Costa-Bauzá; J Perelló; B Isern; P Sanchis; F Grases
Journal:  BMC Urol       Date:  2006-07-05       Impact factor: 2.264

7.  An empirical study on hospital-based prevention of recurrent urinary stone disease in Germany.

Authors:  Alina Reicherz; Patricia Rausch; Roman Herout; Joachim Noldus; Peter Bach
Journal:  World J Urol       Date:  2021-08-18       Impact factor: 4.226

8.  Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence?

Authors:  Hakan Hasbey Koyuncu; Faruk Yencilek; Bilal Eryildirim; Kemal Sarica
Journal:  Urol Res       Date:  2010-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.